# Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

Source: https://onco.cc/trials/nct06909877/  
OnCo record `nct06909877` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of HH2853 Tablets in peripheral T-cell lymphomas, run by Haihe Biopharma Co., Ltd., now recruiting.

## Summary

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma is a phase 1/2 interventional study registered as NCT06909877 by Haihe Biopharma Co., Ltd., with 100 participants planned, started 2022-07-27 and due to reach its primary completion in 2025-10-31. Interventions recorded: HH2853 Tablets.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06909877
- Phase: 1/2
- Setting: An Open-label, Multinational, Multicenter, Single-arm Phase Ⅰb/Ⅱ Study to Evaluate Efficacy and Safety of Oral HH2853, a Selective EZH1/2 Inhibitor, in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma
- Sponsor: Haihe Biopharma Co., Ltd.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06909877: https://clinicaltrials.gov/study/NCT06909877

## Connected records

- cancers: [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- companies: [Haihe Biopharma](https://onco.cc/companies/haihe-biopharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06909877.json